Single-center, Randomized, Double-blind, Placebo-controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cells) in Healthy People Aged 6-17 Years

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant COVID-19 vaccine - WestVac Biopharma/West China Hospital Sichuan University (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Westvac Biopharma

Most Recent Events

23 Apr 2024 Planned End Date changed from 30 Apr 2023 to 1 Dec 2025.
23 Apr 2024 Planned primary completion date changed from 31 Jul 2022 to 1 Dec 2024.
23 Apr 2024 Planned initiation date changed from 7 Mar 2022 to 1 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight